Novel Agents and Emerging Treatment Strategies in Multiple Sclerosis

Jodie M. Burton; Fiona Costello

JOURNAL

Clinical Medicine Reviews in Therapeutics

Novel Agents and Emerging Treatment Strategies in Multiple Sclerosis

Submit a Paper

Jodie M. Burton and Fiona Costello

Clinical Medicine Reviews in Therapeutics 2011:3

Review

Published on 22 Jun 2011

DOI: 10.4137/CMRT.S2895

Further metadata provided in PDF

Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Reviews in Therapeutics

Abstract and Sharing
Article Metrics
Discuss

Abstract

In the past decade, the treatment of multiple sclerosis has undergone a significant paradigm shift. Weekly to daily self-injections of moderate benefit are making way for more effective therapies with improved relapse and disability impact with more appealing routes and frequencies of administration. Some such therapies, like natalizumab, belong to the monoclonal antibody family, while others offer novel immunomodulatory mechanisms and the much sought after oral route of administration. While novel and more powerful immune mechanisms present new issues with respect to adverse effects, these new therapies offer significant advances in the quality of patient care.

Downloads

RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation (BIBDESK, LATEX)

What Your Colleagues Say About Libertas Academica

Publishing in Cancer Informatics was the fastest publication I have ever experienced and has received the highest viewing rate. So it is a great place to publish your very latest research.

Dr Yue Zhang (Boston, MA, USA)

More Testimonials